Humana (NYSE:HUM) – Investment analysts at Leerink Swann dropped their Q1 2018 earnings per share (EPS) estimates for shares of Humana in a report issued on Monday, April 16th. Leerink Swann analyst A. Gupte now expects that the insurance provider will earn $3.21 per share for the quarter, down from their previous forecast of $3.25. Leerink Swann currently has a “Outperform” rating and a $300.00 target price on the stock. Leerink Swann also issued estimates for Humana’s Q3 2018 earnings at $3.96 EPS and Q4 2018 earnings at $2.69 EPS.
Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, February 7th. The insurance provider reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $2.00 by $0.06. The business had revenue of $13.19 billion during the quarter, compared to the consensus estimate of $13.14 billion. Humana had a net margin of 4.55% and a return on equity of 16.13%. The company’s quarterly revenue was up 2.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.34 earnings per share.
A number of other equities research analysts also recently commented on the stock. Argus lifted their price target on shares of Humana from $270.00 to $330.00 and gave the stock a “buy” rating in a report on Monday. Zacks Investment Research upgraded shares of Humana from a “hold” rating to a “buy” rating and set a $316.00 target price for the company in a report on Friday. Piper Jaffray restated a “buy” rating and issued a $313.00 target price on shares of Humana in a report on Wednesday, April 4th. ValuEngine upgraded shares of Humana from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Finally, JPMorgan Chase boosted their target price on shares of Humana from $253.00 to $271.00 and gave the company a “neutral” rating in a report on Monday, February 12th. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $277.05.
Shares of NYSE HUM opened at $289.95 on Tuesday. The stock has a market cap of $39,600.76, a PE ratio of 24.76, a PEG ratio of 1.55 and a beta of 0.97. Humana has a 12 month low of $210.01 and a 12 month high of $293.35. The company has a quick ratio of 1.85, a current ratio of 1.85 and a debt-to-equity ratio of 0.48.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Certified Advisory Corp acquired a new position in shares of Humana during the fourth quarter worth $109,000. American Beacon Advisors Inc. acquired a new position in shares of Humana during the fourth quarter worth $122,000. YorkBridge Wealth Partners LLC lifted its position in shares of Humana by 99.0% during the fourth quarter. YorkBridge Wealth Partners LLC now owns 597 shares of the insurance provider’s stock worth $159,000 after purchasing an additional 297 shares in the last quarter. Daiwa SB Investments Ltd. lifted its position in shares of Humana by 44.9% during the fourth quarter. Daiwa SB Investments Ltd. now owns 710 shares of the insurance provider’s stock worth $176,000 after purchasing an additional 220 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of Humana during the fourth quarter worth $204,000. Institutional investors own 96.42% of the company’s stock.
In other Humana news, CEO Bruce D. Broussard sold 14,075 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $274.32, for a total transaction of $3,861,054.00. Following the completion of the sale, the chief executive officer now directly owns 113,896 shares in the company, valued at $31,243,950.72. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider M Todoroff Christopher sold 16,389 shares of the business’s stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $273.37, for a total transaction of $4,480,260.93. Following the sale, the insider now owns 13,447 shares of the company’s stock, valued at $3,676,006.39. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 31,660 shares of company stock valued at $8,668,218. 0.60% of the stock is owned by insiders.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 27th. Shareholders of record on Friday, March 30th will be paid a dividend of $0.50 per share. This is an increase from Humana’s previous quarterly dividend of $0.40. This represents a $2.00 annualized dividend and a yield of 0.69%. The ex-dividend date of this dividend is Wednesday, March 28th. Humana’s payout ratio is currently 17.08%.
WARNING: “Humana (HUM) Expected to Earn Q1 2018 Earnings of $3.21 Per Share” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another publication, it was stolen and republished in violation of United States & international trademark and copyright laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/04/17/humana-hum-expected-to-earn-q1-2018-earnings-of-3-21-per-share.html.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.